PAVmed, Inc. Stock

$0.60

0.55% day before yesterday

Nasdaq, Jul 18, 10:00 pm CET

ISIN

US70387R1068

Symbol

PAVM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

PAVmed, Inc. Stock price

$0.60

-27.32 97.84% 5Y

Nasdaq, Closing price Fri, Jul 18 2025

+0.00 0.55%

ISIN

US70387R1068

Symbol

PAVM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$10.4m

Enterprise Value

$14.0m

Net debt

$3.6m

Cash

$3.1m

Shares outstanding

16.8m

Valuation (TTM | estimate)

P/E

0.4 | 3.3

P/S

5.2 | 69.8

EV/Sales

7.0 | 93.6

EV/FCF

negative

P/B

0.2

Financial Health

Equity Ratio

-8.1%

Return on Equity

-1,281.2%

ROCE

-83.4%

ROIC

Debt/Equity

0.1

Financials (TTM | estimate)

Revenue

$2.0m | $149.4k

EBITDA

$-35.7m | $-18.9m

EBIT

$-35.9m | $-21.8m

Net Income

$72.5m | $3.1m

Free Cash Flow

$-22.1m

Growth (TTM | estimate)

Revenue

-34.1% | -95.0%

EBITDA

41.0% | 56.4%

EBIT

42.5% | 50.9%

Net Income

202.0% | -90.4%

Free Cash Flow

55.1%

EPS

$1.4

FCF per Share

$-1.3

Short interest

2.3%

Employees

Rev per Employee

$80.0k

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

PAVmed, Inc. Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a PAVmed, Inc. forecast:

7x Buy

88%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a PAVmed, Inc. forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from PAVmed, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	1.99 1.99	34% 34% 100%
- Direct Costs	3.13 3.13	54% 54% 157%
Gross Profit	-1.14 -1.14	70% 70% -57%
- Selling and Administrative Expenses	30 30	33% 33% 1,497%
- Research and Development Expense	4.78 4.78	61% 61% 240%
EBITDA	-36 -36	41% 41% -1,794%
- Depreciation and Amortization	0.19 0.19	90% 90% 10%
EBIT (Operating Income) EBIT	-36 -36	43% 43% -1,804%
Net Profit	72 72	202% 202% 3,641%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

PAVmed, Inc. Stock News

Neutral

PRNewsWire

●

4 days ago

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

Virtual public CAC meeting to be held September 4, 2025, at 2:00 p.m. ET NEW YORK , July 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that on Thursday, September 4, 2025, from 2:00 to 4:00 p.m.

Neutral

PRNewsWire

●

26 days ago

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

Private placement yields $2.5 million from the sale of Veris Health common stock at a $35 million pre-money valuation. NEW YORK , June 24, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary, Veris Health I...

Neutral

PRNewsWire

●

about one month ago

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK , June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), tod...

More PAVmed, Inc. News

Company Profile

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Head office	United States
CEO	Lishan Aklog
Employees	39
Founded	2014
Website	pavmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now